Where do I get help right now?

Contact your local emergency number or a crisis service. In the United States, call or text 988 for the Suicide and Crisis Lifeline. In the UK and Ireland, Samaritans can be reached free on 116 123 at any hour.

My mood has dropped. Should I just stop taking it?

The labelled instruction to discontinue is written for the clinician monitoring you rather than as something to action alone, and stopping without telling anyone removes the person who would be watching what happens next. Contact your prescriber promptly and describe what has changed. If you are having thoughts of harming yourself, contact a crisis service or emergency number first, ahead of anything else.

My partner says I seem flat. I feel fine.

Worth raising even so. The labelling wording covers unusual changes in mood or behaviour, and behaviour is often visible to somebody else before it is visible from the inside. Take the observation to your prescriber as an observation, rather than deciding first whether you agree with it.

GLP-1 and Mental Health: What the Data Show

What this page establishes

Weight-management GLP-1 labelling directs monitoring for depression, suicidal thoughts or unusual mood changes, and discontinuation if they emerge.
Reduced alcohol consumption on semaglutide has been demonstrated in randomised trials, indicating real effects on reward-driven behaviour.
The 988 Suicide & Crisis Lifeline is reachable by call or text on 988, or by chat at 988lifeline.org, free and confidential, 24/7 across the United States and its territories.
Samaritans is reachable free on 116 123 day or night from landlines and mobiles across the UK and Ireland, including pay-as-you-go with no credit, and the number does not appear on the phone bill.

Quick answers

Where do I get help right now?
Contact your local emergency number or a crisis service. In the United States, call or text 988 for the Suicide and Crisis Lifeline.
Read the full answer
In the UK and Ireland, Samaritans can be reached free on 116 123 at any hour.
My mood has dropped. Should I just stop taking it?
The labelled instruction to discontinue is written for the clinician monitoring you rather than as something to action alone, and stopping without telling anyone removes the person who would be watching what happens next.
Read the full answer
Contact your prescriber promptly and describe what has changed. If you are having thoughts of harming yourself, contact a crisis service or emergency number first, ahead of anything else.
My partner says I seem flat. I feel fine.
Worth raising even so. The labelling wording covers unusual changes in mood or behaviour, and behaviour is often visible to somebody else before it is visible from the inside.
Read the full answer
Take the observation to your prescriber as an observation, rather than deciding first whether you agree with it.

Awaiting clinician review. Suicidality and mood-risk content. The research flagged this page as requiring review by a qualified clinician before it goes on a public URL. The crisis-line contacts were added by the writer, outside the research fact base, and have since been verified against the operators’ own sites. The reviewer should confirm them regardless. Until that review happens this page stays behind noindex, and nothing on it should be treated as settled guidance.

Weight-management GLP-1 labelling directs monitoring for depression, suicidal thoughts and unusual mood changes, and discontinuation if they emerge. That instruction is the operative fact on this page, and it stands regardless of how the population-level suicidality signal is eventually interpreted. If your mood has changed since starting, tell your prescriber. If you are having thoughts of harming yourself, stop reading and contact a crisis service or emergency number now. The rest of this page covers what is known about mechanism, what confounds any attempt to attribute a mood change to the drug, and why that attribution is harder than it looks.

If you need help now

Thoughts of suicide or self-harm need a person, not an article. Contact your local emergency number, go to an emergency department, or call a crisis line. In the United States, the 988 Suicide and Crisis Lifeline is reachable by calling or texting 988. In the United Kingdom and Ireland, Samaritans can be reached on 116 123, free, at any hour.

Telling your prescriber is important too, because the label directs discontinuation if suicidal thoughts emerge. Getting immediate support comes first.

Do not wait for a routine appointment Thoughts of self-harm or suicide warrant immediate contact with a crisis service or emergency number. New or worsening depression or anxiety warrants contacting your prescriber promptly rather than waiting to see whether it passes.

What the labels say

Weight-management GLP-1 labelling instructs monitoring for depression, suicidal thoughts and unusual changes in mood or behaviour, and discontinuation if those symptoms occur.

That wording is worth quoting rather than paraphrasing, because paraphrase tends to soften it in one direction or dramatise it in the other. It exists because regulators required a monitoring instruction, and it applies whatever your view of the underlying signal.

What it means for you in practice is simple. A mood change on this drug is something your prescriber has a labelled instruction to act on. It is not a complaint you need to justify before raising.

The suicidality question

Reports of suicidal ideation in people taking GLP-1 receptor agonists prompted regulatory review, and the labelling monitoring language is what sits on the products now.

This page reports that position rather than adjudicating the signal. Reviewing a pharmacovigilance signal requires access to case-level data and the statistical machinery regulators apply to it, and a health information site is not the venue for reaching a verdict on one.

So the honest summary: the concern was taken seriously enough to generate label language directing monitoring and discontinuation, and that instruction is what your clinician works from.

Reward circuitry and reports of emotional flatness

GLP-1 receptors are expressed in reward-processing regions including the ventral tegmental area and nucleus accumbens, alongside the hypothalamus and brainstem. Those regions assign motivational salience to rewards in general, not only to food.

There is randomised evidence that this reaches beyond eating. A 2025 JAMA Psychiatry trial of once-weekly semaglutide in adults with alcohol use disorder found reduced alcohol consumption. That is a real effect on reward-driven behaviour, demonstrated in a randomised design rather than inferred.

Which makes the widely reported experience of emotional flatness or reduced enjoyment plausible in principle. It is worth being precise about its status: emotional blunting and anhedonia on GLP-1s are commonly reported but are not established labelled reactions and have not been quantified in trials. Plausible mechanism, absent measurement. Report it to your prescriber anyway, because the label's monitoring instruction covers unusual mood changes.

Reported, not measured Emotional flatness is one of the most common things people describe on this drug class and one of the least studied. This site will not present it as an established effect, and will not dismiss it either. It belongs in the conversation with your prescriber.

Weight loss moves mood in both directions

Any attempt to attribute a mood change to the drug runs into the fact that substantial weight loss changes mood by itself, and not always in one direction.

For many people it improves mood, self-efficacy and physical function. Moving more easily, sleeping better, and seeing a long-standing goal move all lift mood in ways that have nothing to do with receptor pharmacology.

Working the other way, rapid loss brings fatigue, disturbed sleep and often inadequate nutrition, each of which depresses mood independently. Cardiorespiratory fitness does not improve on GLP-1 treatment alone in randomised data, so someone who is lighter but not fitter may feel worse rather than better. Expectations play a part too, and so does the reaction of other people to a changing body, which is not always the reaction anyone wanted.

So the same person can have three or four things pushing their mood in different directions at once. That is why clinical assessment beats self-diagnosis here, and why a clinician will ask about sleep, nutrition and life circumstances before attributing anything to the drug.

Eating disorder history

This deserves naming directly. A drug that suppresses appetite, quiets thoughts about food and drives weight loss interacts with a restrictive eating history in ways that are not always visible from outside, including to the person experiencing them.

The trials excluded people with significant active psychiatric illness in many cases, so trial populations do not represent everyone now prescribed these drugs. That gap is worth knowing about, since it means the reassurance the trial safety data offer does not extend cleanly to everybody.

If you have a history of anorexia, bulimia, binge eating disorder or any pattern of restriction, that is a specific conversation to have before starting, and a reason to have support in place while taking it. Eating disorder services are the right route, and using them early is easier than using them late.

Restriction that feels compulsive is a reason to reach out Appetite suppression can make restriction feel effortless and reasonable. If eating less has started to feel like something you cannot stop rather than something you chose, contact your clinician or an eating disorder support service.

Fatigue, nutrition and sleep as confounders

Undernutrition depresses mood. So does poor sleep. Both are common during rapid weight loss, and both are addressable in ways that a mood symptom attributed straight to the drug is not.

Protein intake frequently drops when total intake drops, and micronutrient intake with it. Someone eating very little for months will feel flat, and that is worth checking before concluding the receptor pharmacology is responsible.

None of that means a mood change is your fault or something to fix by trying harder. It means there are several places to look, and a clinician can look at all of them.

When to contact a clinician

Thoughts of self-harm or suicide, which need immediate help rather than an appointment
New or worsening depression or anxiety
Loss of interest or pleasure in activities beyond food
Eating that has become restrictive in a way that feels compulsive
Any personal history of an eating disorder, ideally raised before starting
Mood changes alongside marked fatigue or very low food intake

Not medical advice

This page reports labelling language and published research. It is general educational information, not advice about your mental health or your treatment, and it is not a substitute for assessment by a clinician. If you are in crisis, contact emergency services or a crisis line rather than reading further.

The evidence, one row per claim

Claim	Tier	Source
Weight-management GLP-1 labelling directs monitoring for depression, suicidal thoughts or unusual mood changes, and discontinuation if they emerge.	established	WEGOVY US Prescribing Information, FDA
GLP-1 receptors are expressed in reward-processing regions, which is the proposed basis for effects on motivation and wanting beyond food.	emerging	GLP-1 agonists and reward circuitry (PMC)
Reduced alcohol consumption on semaglutide has been demonstrated in randomised trials, indicating real effects on reward-driven behaviour.	established	Once-Weekly Semaglutide in Adults With Alcohol Use Disorder, JAMA Psychiatry 2025
Reports of emotional blunting or anhedonia on GLP-1s are not established labelled reactions and lack trial quantification.	anecdotal	unsourced
The trials excluded people with significant active psychiatric illness in many cases, so trial populations do not represent everyone now prescribed these drugs.	emerging	WEGOVY US Prescribing Information (trial population description)
The 988 Suicide & Crisis Lifeline is reachable by call or text on 988, or by chat at 988lifeline.org, free and confidential, 24/7 across the United States and its territories.	established	988 Suicide & Crisis Lifeline (operator site, verified 2026-08-23)
Samaritans is reachable free on 116 123 day or night from landlines and mobiles across the UK and Ireland, including pay-as-you-go with no credit, and the number does not appear on the phone bill.	established	Samaritans (operator site, verified 2026-08-23)

Questions people ask

Does this settle once I reach a stable dose?

Nothing published establishes a timing pattern for mood effects on this class, and the labelled monitoring instruction has no end date tied to reaching maintenance. Emotional flatness in particular is widely described and has never been quantified in a trial. A change that persists is something to report rather than something to wait out.

Sources

Where this comes from

Researched and edited by Thomas Prommer — biohacker, performance athlete, data enthusiast and health coach.

Every number on this page traces to a named source. There are 7 sourced claims below the fold, each with the document it came from.

Sources consulted: WEGOVY US Prescribing Information, GLP-1 agonists and reward circuitry, Once-Weekly Semaglutide in Adults With Alcohol Use Disorder, unsourced, 988 Suicide & Crisis Lifeline and 1 more.

Sources last read 2026-08-23.

Keep reading

Educational content, reviewed 2026-08-23. Not medical advice, not a prescription, and not a substitute for a clinician who knows your history. Doses named here are label schedules or doses used in named trials, never a recommendation to you.

GLP-1 and Mental Health: Mood, Anxiety and What the Data Show